Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Compact Microtox® PD launch scheduled for Q1 2022

10 Dec 2021 07:00

RNS Number : 2004V
Deepverge PLC
10 December 2021
 

10 December 2021

 

DeepVerge PLC

 

("DeepVerge" or "Company")

 

Launch of compact Microtox® PD[i] surveillance units in Q1 2022

 

Detects SARS-CoV-2 and a range of pathogens at local, regional and national levels

 

New service bridges gap between real-time detection and variant identification where people gather

 

Modern Water, a division of DeepVerge (AIM: DVRG) announces the completion of development of the 3rd generation compact Microtox® PD COVID detection system, which is now scheduled for launch in the first quarter of 2022. The upgraded Microtox® PD system significantly expands pandemic surveillance capabilities to towns, villages, hospitals, hotels, ports, locations where large groups of people gather, extending the reach of real-time national pandemic response to local community level.

 

Modern Water Mobile Services ("MWMS")

 

MWMS is positioned as a critical new component in the armoury of national and provincial government response protocol. It allows utilities to extend their reach into smaller sites for more granular 'last mile' surveillance, enabling local authorities and private companies to protect citizens and customers by monitoring for COVID and a range of additional pathogens, including forever chemicals.

 

Benefits include:

 

1. Real-time detection of the virus in the community at source,

2. Zero transport costs of non-virus confirmed samples, and

3. Variant testing only on confirmed virus at the laboratory.

 

Gerry Brandon, CEO of DeepVerge plc, commented:

 

"Size, cost, reach and route to market have been heavily thought through with our new 3rd generation designs. The units are now smaller - allowing them to be installed for smaller populations; mobile - allowing them to be taken to where populations gather; mass producible - allowing more affordability for customers; and just as importantly, available for new partner opportunities. We have also built into our business model the capability for these units to be manufactured and franchised to companies in the developing world, to be sold at locally affordable prices.

 

"Over the last 18 months, we recognised the potential of our tech for mass surveillance for the benefit of public health - from monitoring large populations down to individual monitoring. It is our vision for Microtox® PD to become a standard part of home or office utility and this latest generation model is a giant leap towards that vision being reality."

 

Microtox® BT

 

The Microtox® BT equipment was also re-designed to deliver a portable, mobile testing unit to process breath tests at point of care. The established test protocols have been carried out at Labskin from test subjects provided by the Royal College of Surgeons in Ireland for the early prototype and secured positive results. Regulatory approvals for human diagnostic equipment is evaluated on test equipment that will be used on humans. Therefore, roll out of the breath test is subject to meeting the satisfactory requirements of EU Regulatory approvals which will be carried out on the latest version of the Microtox® BT units. Further information on this will be provided in H1 2022.

 

 

Enquiries:

 

DeepVerge plc

Gerry Brandon, CEO

+44 (0) 734 0055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About DeepVerge plc (www.deepverge.com)

 

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 


[i] Microtox® PD has been designed to be retrofitted into existing Modern Water equipment to detect and identify a range of infectious viruses and bacteria including SARS-CoV-2, E.coli, Legionella and Cryptosporidium, on a single chip, using AI, in real-time. New compact version is 100% portable.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKCBNFBDDPBK
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.